Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Haichuan Hu, Ph.D.

Concepts

This page shows the publications Haichuan Hu has written about Humans.
Connection Strength

0.065
  1. Unlocking Better Survival for Esophageal Cancer Patients: Is Thoracic Duct Resection the Key? Ann Surg Oncol. 2021 Aug; 28(8):4086-4087.
    View in: PubMed
    Score: 0.011
  2. The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds. J Thorac Oncol. 2016 12; 11(12):2161-2172.
    View in: PubMed
    Score: 0.008
  3. Putatively functional PLCE1 variants and susceptibility to esophageal squamous cell carcinoma (ESCC): a case-control study in eastern Chinese populations. Ann Surg Oncol. 2012 Jul; 19(7):2403-10.
    View in: PubMed
    Score: 0.006
  4. Is anterior mediastinum route a shorter choice for esophageal reconstruction? A comparative anatomic study. Eur J Cardiothorac Surg. 2011 Dec; 40(6):1466-9.
    View in: PubMed
    Score: 0.005
  5. Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma: Clinicopathologic and Molecular Study in a Large Series of Cases. Am J Clin Pathol. 2018 May 31; 150(1):65-73.
    View in: PubMed
    Score: 0.002
  6. Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma: Three-year Survival of a Prospective, Randomized, Open-label Trial. Ann Surg. 2018 05; 267(5):826-832.
    View in: PubMed
    Score: 0.002
  7. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clin Cancer Res. 2018 01 01; 24(1):197-208.
    View in: PubMed
    Score: 0.002
  8. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016 Mar; 22(3):262-9.
    View in: PubMed
    Score: 0.002
  9. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res. 2015 Sep 01; 21(17):3924-33.
    View in: PubMed
    Score: 0.002
  10. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J Thorac Oncol. 2014 Jun; 9(6):760-8.
    View in: PubMed
    Score: 0.002
  11. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res. 2014 Aug 01; 20(15):4107-14.
    View in: PubMed
    Score: 0.002
  12. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 01; 145(3):473-479.
    View in: PubMed
    Score: 0.002
  13. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014 May; 84(2):121-6.
    View in: PubMed
    Score: 0.002
  14. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One. 2014; 9(2):e88291.
    View in: PubMed
    Score: 0.002
  15. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014 Dec; 21 Suppl 4:S490-6.
    View in: PubMed
    Score: 0.002
  16. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One. 2013; 8(7):e69016.
    View in: PubMed
    Score: 0.002
  17. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S577-82.
    View in: PubMed
    Score: 0.002
  18. Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PLoS One. 2012; 7(12):e51748.
    View in: PubMed
    Score: 0.002
  19. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012 Dec 10; 30(35):4352-9.
    View in: PubMed
    Score: 0.002
  20. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2013 Jan; 79(1):8-13.
    View in: PubMed
    Score: 0.002
  21. Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience. J Thorac Cardiovasc Surg. 2012 Oct; 144(4):778-85; discussion 785-6.
    View in: PubMed
    Score: 0.001
  22. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012 Sep 01; 18(17):4725-32.
    View in: PubMed
    Score: 0.001
  23. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012 Apr 01; 18(7):1947-53.
    View in: PubMed
    Score: 0.001
  24. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012 Jan; 7(1):85-9.
    View in: PubMed
    Score: 0.001
  25. A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer. J Proteomics. 2011 Apr 01; 74(4):528-38.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.